Faron Pharmaceuticals with Interim CFO

Yrjö Wichmann previously served as CFO of the company between 2014 and 2019. Most recently, he held the position of Senior Vice President, Financing & IR at Faron. Prior to joining Faron, Wichmann held a number of senior management positions in life sciences and biotechnology at IP Finland Oy, Biohit Oyj, CapMan Oyj, FibroGen Europe Oyj and D. Carnegies & Co AB. He is a member of the investment committee of Dasos Timberland Fund I and II and a board member of Nordic Science Investment Oy. Wichmann holds a Master’s degree in Economics from the University of Helsinki.
“As a former CFO of this Company and, most recently, our Senior Vice President, Financing & IR, Yrjö is well positioned to take up the role of Interim CFO whilst we look for a permanent replacement.” said Faron-CEO, Dr. Markku Jalkanen.
Faron is based in Turku and Boston. The global, clinical-stage biopharmaceutical company is focused on tackling cancers via novel immunotherapies.